Aspirin — Benefits Deep Dive

Aspirin (acetylsalicylic acid) is the most widely studied medication in human history — appearing in more than 200,000 indexed peer-reviewed publications and prescribed continuously for 125 years since Bayer introduced it in 1899. Its therapeutic value lies in a single elegant chemistry: aspirin irreversibly acetylates the serine-529 residue of cyclooxygenase-1 (COX-1) in platelets, abolishing thromboxane A2 production for the platelet's entire 7-10 day lifespan. That single biochemical event drives cardiovascular benefit (less platelet aggregation), colorectal cancer chemoprevention (reduced prostaglandin-driven tumorigenesis), and the major bleeding risk that defines its therapeutic boundary. Four deep-dive pages below dissect each application — secondary versus primary cardiovascular prevention, the colorectal cancer signal, hemorrhage risk stratification, and the low-dose (75-100 mg) versus full-dose (325 mg+) question that drives most modern prescribing decisions.

Deep-Dive Articles

Cardiovascular Prevention

The flagship indication. Mechanism of irreversible COX-1 acetylation in anucleate platelets, why secondary prevention (after prior MI, stroke, or stent) remains uncontroversial with ~25% relative risk reduction in recurrent events, the dramatic 2018 reversal in primary prevention guidelines (ARRIVE, ASCEND, ASPREE trials), and why the USPSTF now restricts primary-prevention aspirin to adults 40-59 with elevated 10-year ASCVD risk and no bleeding risk factors.

Colorectal Cancer Risk

The most robust cancer chemoprevention signal for any drug. The Rothwell pooled analyses of 4 long-term aspirin trials showed a 24% reduction in colorectal cancer incidence and 35% reduction in colorectal cancer mortality after 10+ years. Mechanism via COX-2 inhibition in colonic epithelium, the CAPP2 trial proving benefit in Lynch syndrome carriers, the latency requirement (5-10 years before benefit emerges), and why the latency requirement collides with bleeding risk in older adults.

Bleeding Risks and Cautions

The factor that limits every aspirin recommendation. Quantitative bleeding risk (GI hemorrhage roughly 0.3%/year on low-dose, hemorrhagic stroke ~0.05%/year), risk stratification by age and prior GI history, the H. pylori interaction, proton pump inhibitor co-therapy, perioperative bridging, the dangerous NSAID + aspirin combination, and the absolute contraindications (active bleed, severe thrombocytopenia, recent hemorrhagic stroke).

Low Dose vs Full Dose

Why 81 mg is the canonical "baby aspirin" dose in the United States and 75 mg or 100 mg elsewhere. The ADAPTABLE trial (15,076 patients, 2021) showed no difference between 81 mg and 325 mg for secondary cardiovascular prevention — settling a 50-year controversy. When higher doses are still indicated (Kawasaki disease, polycythemia vera, certain pain syndromes), enteric coating versus uncoated, chewable for acute MI, and the dose-response curve for bleeding (linear) versus benefit (plateau above 75 mg).

Back to Table of Contents

Table of Contents

  1. Deep-Dive Articles
  2. Why One Mechanism Produces So Many Effects
  3. Research Papers: Cardiovascular Prevention
  4. Research Papers: Colorectal Cancer
  5. Research Papers: Bleeding Risks
  6. Research Papers: Dosing & Pharmacology
  7. Research Papers: Cross-Cutting (Mechanism, History, Safety)
  8. External Authoritative Resources
  9. Connections

Why One Mechanism Produces So Many Effects

Most drugs reach broad therapeutic application by gradually being discovered to act on multiple targets. Aspirin took the opposite path: it began with one observed clinical effect (anti-inflammatory and analgesic willow-bark folk medicine, formalized into salicylic acid in 1828 and acetylated to acetylsalicylic acid by Felix Hoffmann at Bayer in 1897), and over the next century the unified mechanism explaining all of its uses was progressively uncovered.

In 1971, John Vane at the Royal College of Surgeons in London showed that aspirin and other NSAIDs inhibit prostaglandin synthesis — work that won the 1982 Nobel Prize in Physiology or Medicine. The specific target turned out to be cyclooxygenase (COX), the enzyme that converts arachidonic acid to prostaglandin H2, the precursor of all downstream prostaglandins and thromboxanes. Aspirin is uniquely irreversible among NSAIDs: it acetylates a serine residue (Ser-529 in COX-1, Ser-516 in COX-2) at the active site entrance, permanently blocking the enzyme until new protein is synthesized.

This irreversibility produces aspirin's most clinically important property: platelets, which lack nuclei, cannot synthesize new COX-1. A single low dose of aspirin (75-100 mg) acetylates the entire platelet COX-1 pool, abolishing thromboxane A2 production for the platelet's 7-10 day lifespan. The endothelium and other nucleated cells regenerate COX within hours, so prostacyclin (PGI2, a vasodilator and platelet inhibitor) recovers quickly. The net effect is a sustained, near-pure antiplatelet effect from a tiny daily dose.

  1. Cardiovascular benefit — reduced thromboxane-A2-driven platelet aggregation in the coronary and cerebral circulation prevents arterial thrombi forming on ruptured atherosclerotic plaques. See Cardiovascular Prevention.
  2. Colorectal cancer chemoprevention — reduced COX-2-derived prostaglandin E2 in colonic epithelium decreases the prostaglandin-driven proliferation, angiogenesis, and apoptosis-resistance that promote adenoma-to-carcinoma progression. See Colorectal Cancer Risk.
  3. Anti-inflammatory and analgesic effect — the original observed effect, mediated by COX-2 inhibition in inflamed tissue reducing prostaglandin E2 and prostacyclin nociceptor sensitization. Full doses (650-1000 mg every 4-6 hours) are required.
  4. Anti-pyretic effect — aspirin lowers fever by inhibiting prostaglandin E2 production in the hypothalamic preoptic area, where PGE2 resets the body's temperature setpoint upward. This effect underlies its century-long use as a fever reducer.
  5. The downside: GI mucosal injury and bleeding — the same COX-1 inhibition that prevents platelet aggregation also reduces gastric prostaglandins that maintain the mucus and bicarbonate layer protecting the stomach lining. See Bleeding Risks and Cautions.

The unified mechanism explains the dose-response asymmetry that defines modern aspirin prescribing. The platelet effect saturates at 75-100 mg daily; the analgesic effect requires 325-650 mg; the anti-inflammatory effect requires 2400-4000 mg daily (now rarely used due to NSAID alternatives). Bleeding risk, however, increases linearly with dose. The deep-dive on Low Dose vs Full Dose explores why 81 mg has become the canonical cardioprotective dose.

Back to Table of Contents

Research Papers: Cardiovascular Prevention

  1. Antithrombotic Trialists' (ATT) Collaboration meta-analysis — 195 trials, 135,000 patients, secondary prevention benefit — PubMed PMID 12096097
  2. ISIS-2 trial (Second International Study of Infarct Survival): aspirin in acute MI — PubMed PMID 2899772
  3. ARRIVE trial: aspirin primary prevention in moderate-risk adults — PubMed PMID 30158069
  4. ASCEND trial: aspirin for primary prevention in diabetes — PubMed PMID 30146931
  5. ASPREE trial: aspirin in healthy older adults — PubMed PMID 30221597
  6. USPSTF 2022 recommendation on aspirin for primary CV prevention — PubMed PMID 35471505
  7. Physicians' Health Study (1989 NEJM): aspirin primary prevention foundation trial — PubMed PMID 2664509
  8. CAPRIE trial: clopidogrel vs aspirin in atherothrombotic events — PubMed PMID 8918275
  9. CURE trial: aspirin plus clopidogrel in acute coronary syndromes — PubMed PMID 11519503
  10. Women's Health Study: aspirin primary prevention in women (NEJM 2005) — PubMed PMID 15753114

Back to Table of Contents

Research Papers: Colorectal Cancer

  1. Rothwell PM et al., Lancet 2010: long-term aspirin and colorectal cancer incidence/mortality — PubMed PMID 20970847
  2. Rothwell PM et al., Lancet 2011: effect of daily aspirin on 20-year cancer mortality (pooled analysis) — PubMed PMID 21144578
  3. CAPP2 trial: aspirin in Lynch syndrome carriers — PubMed PMID 22122850
  4. CAPP2 10-year follow-up confirming Lynch syndrome benefit — PubMed PMID 32534647
  5. Chan AT et al., JAMA 2005: aspirin dose and colorectal cancer in women (Nurses' Health Study) — PubMed PMID 16091571
  6. Cole BF et al., NEJM 2003: aspirin for prevention of colorectal adenomas — PubMed PMID 12621136
  7. Baron JA et al., NEJM 2003: low-dose aspirin and colorectal adenoma prevention — PubMed PMID 12621137
  8. Cuzick J et al., Annals of Oncology 2015: aspirin for cancer prevention — benefit-risk analysis — PubMed PMID 25096604
  9. Chan AT et al., JAMA 2009: aspirin use and survival after colorectal cancer diagnosis — PubMed PMID 19690313
  10. Drew DA et al., Nature Reviews Cancer 2016: aspirin and colorectal cancer chemoprevention mechanisms — PubMed PMID 27009395

Back to Table of Contents

Research Papers: Bleeding Risks

  1. Lanas A et al., AJG 2011: GI bleeding risk with low-dose aspirin — PubMed PMID 21931380
  2. McQuaid KR & Laine L, Am J Med 2006: systematic review of low-dose aspirin and GI bleeding — PubMed PMID 16490465
  3. Mahady SE et al., ASPREE bleeding analysis (NEJM 2018) — PubMed PMID 30221595
  4. Bhatt DL et al., COGENT trial: PPI co-therapy with aspirin + clopidogrel — PubMed PMID 20925534
  5. Garcia Rodriguez LA et al., BMJ 2011: aspirin and upper GI bleeding population study — PubMed PMID 21300722
  6. Hawkey CJ et al., Aliment Pharmacol Ther 2008: H. pylori eradication and aspirin GI risk — PubMed PMID 18549457
  7. Hochholzer W et al., Eur Heart J 2011: intracranial hemorrhage and antiplatelet therapy — PubMed PMID 21217142
  8. Catella-Lawson F et al., NEJM 2001: ibuprofen blocks aspirin antiplatelet effect — PubMed PMID 11752352
  9. Sostres C & Lanas A, Best Pract Res Clin Gastroenterol 2012: GI effects of aspirin — PubMed PMID 22542154
  10. Bibbins-Domingo K, USPSTF 2016 (superseded): bleeding-benefit balance modeling — PubMed PMID 27064677

Back to Table of Contents

Research Papers: Dosing & Pharmacology

  1. ADAPTABLE trial: 81 mg vs 325 mg aspirin for secondary prevention (NEJM 2021) — PubMed PMID 33999547
  2. Patrono C et al., NEJM 2005: low-dose aspirin pharmacology and clinical use — PubMed PMID 15917386
  3. Roth GJ & Majerus PW, J Clin Invest 1975: acetylation of platelet COX by aspirin (original) — PubMed PMID 1206094
  4. Vane JR, Nat New Biol 1971: aspirin inhibits prostaglandin synthesis (Nobel work) — PubMed PMID 5284360
  5. Cox D et al., Stroke 2006: aspirin resistance and platelet response variability — PubMed PMID 16690893
  6. Eikelboom JW et al., Circulation 2002: aspirin resistance and clinical outcomes — PubMed PMID 12451000
  7. Maree AO et al., JACC 2005: enteric-coated aspirin and platelet response — PubMed PMID 16139140
  8. Newby LK et al., AHA scientific statement 2008: aspirin dose and CV prevention — PubMed PMID 18768461
  9. Rothwell PM et al., Lancet 2018: aspirin body-weight-dose effect on CV events — PubMed PMID 30017552
  10. Patrono C, NEJM 1994: aspirin as antiplatelet drug — mechanism review — PubMed PMID 8052275

Back to Table of Contents

Research Papers: Cross-Cutting (Mechanism, History, Safety)

  1. Mahmud SM et al., JNCI 2010: aspirin and prostate cancer mortality — PubMed PMID 20668233
  2. Algra AM & Rothwell PM, Lancet Oncol 2012: aspirin and cancer incidence/metastasis — PubMed PMID 22440112
  3. Belay ED et al., NEJM 1999: Reye's syndrome and aspirin in children/teens — PubMed PMID 10228191
  4. McNeil JJ et al., NEJM 2018: aspirin and all-cause mortality in healthy older adults — PubMed PMID 30221596
  5. Wilson PWF et al., JACC 2019: ACC/AHA primary prevention guideline aspirin section — PubMed PMID 30894318
  6. Berger JS et al., JAMA 2006: aspirin for primary prevention in women meta-analysis — PubMed PMID 16434631
  7. Newburger JW et al., AHA Kawasaki disease guideline (aspirin dosing) — PubMed PMID 15505111
  8. Landolfi R et al., NEJM 2004: aspirin in polycythemia vera (ECLAP trial) — PubMed PMID 14711909
  9. Sneader W, BMJ 2000: discovery of aspirin (historical) — PubMed PMID 11124166
  10. Jeffreys D, "Aspirin: the remarkable story of a wonder drug" — PubMed: aspirin history

Back to Table of Contents

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents